Sitavia 50 mg (Sitagliptin Phosphate)
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
YuYu Pharmaceutical Co., Ltd.
MFDS item code 201503175 · Approved 2015.05.27
This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used together with diet and exercise to assist in blood sugar control for patients with type 2 diabetes. It can be used as monotherapy, and if blood sugar control is difficult with monotherapy alone in patients who have no experience with diabetes medication, it can be taken in conjunction with Metformin. Additionally, if blood sugar control is insufficient with monotherapy using sulfonylureas, Metformin, thiazolidinediones, or insulin, this medication can be used in combination. Even in cases where multiple medications are used, if blood sugar control remains difficult, this medication can be added to enhance treatment effectiveness. This method assists in improving the patient's blood sugar control status.
This drug is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before and periodically during treatment with this drug. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions after administration, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, usage should be discontinued immediately and medical consultation should be sought. During the usage of this medication, serious inflammation of the pancreas known as pancreatitis may occur; hence, if symptoms like abdominal pain, nausea, or vomiting arise, healthcare personnel must be notified immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in patients allergic to this medication or its components. Patients with decreased kidney function may have slower elimination of the drug, making it important to adjust the dosage or use caution, and regular kidney function tests are essential. Clinical trial results indicate that common side effects when this medication is used alone or in combination with other diabetes medications include upper respiratory infections, headaches, nasopharyngitis, and diarrhea, especially when taken with insulin or sulfonylureas, which may increase the risk of hypoglycemia. If hypoglycemic symptoms occur while taking the medication, blood sugar should be checked immediately, and appropriate action should be taken if necessary, and dose adjustment of insulin or sulfonylureas may be needed. This medication is not recommended for use during pregnancy, and it is also advisable for breastfeeding women to avoid taking it. The safety and efficacy in children and adolescents have not been established, hence it should not be used by individuals under 18 years old. For elderly patients, the risk of decreased kidney function is higher, so dosage adjustment and kidney function monitoring are necessary. In case of overdose, general emergency treatment should be provided, and if necessary, hemodialysis can be performed to remove the drug from the system. While drug interactions with this medication are minimal, changes in blood concentration may occur when used with certain drugs, so consultation with a physician or pharmacist is advised. If severe joint pain or blistering skin occurs during medication use, immediate medical evaluation is required, and if symptoms are severe, the administration of the drug may need to be discontinued. This medication has not reported significant cardiovascular safety issues even with long-term use; however, regular health checkups are recommended.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air exposure and is best kept at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness over time.
Bright beige, convex, round film-coated tablet
30 tablets (10 tablets/PTPX3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
YuYu Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.